The association between theNAT2genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

The association between theNAT2genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis

Published:2018-10-03 Issue:12 Volume:84 Page:2747-2760
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Zhang Min¹²,Wang Shuqiang²³,Wilffert Bob²⁴^ORCID,Tong Rongsheng¹⁵,van Soolingen Dick⁶⁷,van den Hof Susan⁸,Alffenaar Jan-Willem²^ORCID

Affiliation:

1. Department of Pharmacy; Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital; Chengdu China

2. University of Groningen, University Medical Center Groningen; Department of Clinical Pharmacy and Pharmacology; Groningen The Netherlands

3. Department of Infectious Diseases; Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital; Chengdu China

4. Department of Pharmacotherapy, -Epidemiology, & -Economics, Groningen Research Institute of Pharmacy; University of Groningen; Groningen The Netherlands

5. Personalized Drug Therapy Key Laboratory of Sichuan Province

6. Tuberculosis Reference Laboratory; National Institute for Public Health and the Environment (RIVM); Bilthoven The Netherlands

7. Department of Medical Microbiology; Radboud University Medical Centre; Nijmegen The Netherlands

8. KNCV Tuberculosis Foundation; The Hague The Netherlands

Funder

China National Key Specialty Construction Project of clinical pharmacy

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.13722/fullpdf

Reference73 articles.

1. World Health Organization Global tuberculosis report 2016

2. World Health Organization Guidelines for treatment of tuberculosis 2010

3. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis;Yee;Am J Respir Crit Care Med,2003

4. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management;Ramappa;J Clin Exp Hepatol,2013

5. An official ATS statement: hepatotoxicity of antituberculosis therapy;Saukkonen;Am J Respir Crit Care Med,2006

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differential distribution of NAT2 polymorphisms and NAT2 acetylator phenotypes among indigenous populations of the Brazilian Amazon;Pharmacogenetics and Genomics;2024-09-10

2. Isoniazid-induced pancreatitis: A systematic review;Tuberculosis;2024-09

3. Genetic ancestry proportion influences risk of adverse events from tuberculosis treatment in Brazil;2024-08-30

4. Precision Medicine Strategies to Improve Isoniazid Therapy in Patients with Tuberculosis;European Journal of Drug Metabolism and Pharmacokinetics;2024-08-17

5. Characteristics of isoniazid-induced psychosis: a systematic review of case reports and case series;European Journal of Clinical Pharmacology;2024-08-13